XT
FATE icon

XTX Topco’s Fate Therapeutics FATE Stock Holding History

XTX Topco’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$488K Sell
180,826
-208,343
-54% -$386K 0.01% 2484
2026
Q1 		$467K Buy
389,169
+24,431
+7% +$29.7K 0.01% 2112
2025
Q4 		$358K Sell
364,738
-73,180
-17% -$87.9K 0.01% 1913
2025
Q3 		$552K Buy
437,918
+5,590
+1% +$6.03K 0.03% 996
2025
Q2 		$484K Sell
432,328
-26,980
-6% -$31.4K 0.02% 1123
2025
Q1 		$363K Buy
459,308
+209,508
+84% +$257K 0.02% 1262
2024
Q4 		$412K Buy
+249,800
New +$629K 0.03% 941
2024
Q3 		– Sell
-33,898
Closed -$111K – 2237
2024
Q2 		$111K Buy
33,898
+16,510
+95% +$72.3K 0.01% 1395
2024
Q1 		$128K Buy
+17,388
New +$108K 0.02% 1307
2023
Q4 		– Sell
-192,920
Closed -$409K – 1745
2023
Q3 		$409K Buy
192,920
+171,321
+793% +$568K 0.07% 525
2023
Q2 		$103K Sell
21,599
-6,591
-23% -$36.4K 0.02% 1159
2023
Q1 		$161K Sell
28,190
-76,000
-73% -$459K 0.03% 1010
2022
Q4 		$1.05M Buy
104,190
+83,670
+408% +$1.57M 0.22% 76
2022
Q3 		$460K Buy
+20,520
New +$593K 0.11% 275
2021
Q3 		– Sell
-5,039
Closed -$437K – 783
2021
Q2 		$437K Buy
+5,039
New +$406K 0.15% 224

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

XTX Topco's FATE Position: Q2 2026 in Review

XTX Topco reduced its Fate Therapeutics (FATE) stake by 54% in Q2 2026, selling an estimated $386K and leaving 180,826 shares worth $488K. The position accounts for 0.01% of the portfolio, ranked #2484.

XTX Topco first reported a position in FATE in Q2 2021 and has held it in 15 quarters since. The position peaked at $1.05M in Q4 2022. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • XTX Topco held 180,826 shares of Fate Therapeutics worth $488K as of Q2 2026.
  • XTX Topco sold 208,343 Fate Therapeutics shares in Q2 2026, an estimated $386K.
  • Fate Therapeutics made up 0.01% of XTX Topco's portfolio in Q2 2026, its #2484 holding.
  • XTX Topco first reported a position in Fate Therapeutics in Q2 2021 and has held it in 15 quarters since.
  • XTX Topco's Fate Therapeutics position peaked at $1.05M in Q4 2022.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.